Vote Scores

Home / Companies / Galectin Therapeutics Inc. / 3 Dec 2025

Meeting · year to 30 June 202674 filers reporting

Galectin Therapeutics Inc.: meeting of 3 Dec 2025

Votes reported on Form N-PX, item by item

74 Form N-PX filers reported votes at the Galectin Therapeutics Inc. meeting of 3 Dec 2025. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

11 nominees; 91.6% of reported votes for; 4 filers withheld from or voted against at least one nominee.

154 vote records from 10 filers. 1 of the 10 filers that marked the item either way voted against management.

90.0% for0.0% against10.0% other10.0% against management10 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

90 vote records from 74 filers. 4 of the 71 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

89.2% for6.8% against4.1% other5.6% against management74 filers99.8% for0.2% against0.2% against management1,758,630 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 63 filers; three years: 4 filers; for: 1 filer; 1-year: 1 filer; not applicable: 1 filer.

88 vote records from 72 filers. 62 of the 68 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

1.4% for0.0% against98.6% other91.2% against management72 filers0.1% for0.0% against99.9% other94.6% against management1,758,105 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

14 vote records from 10 filers. 1 of the 10 filers that marked the item either way voted against management.

90.0% for10.0% against10.0% against management10 filers99.9% for0.1% against0.1% against management262,844 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no vote *For
BlackRock and iSharesForForSplit or no vote *For
FidelityForForSplit or no vote *For
State Street and SPDRNo reportForSplit or no vote *No report
EquitableForForSplit or no vote *For
Charles SchwabForForSplit or no vote *For
John Hancock and ManulifeForForSplit or no vote *For
Morgan Stanley, Eaton Vance and CalvertNo reportForSplit or no vote *No report
Goldman SachsNo reportForSplit or no vote *No report
Northern Trust and FlexSharesForForSplit or no vote *For
BNY MellonNo reportForSplit or no vote *No report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Galectin Therapeutics Inc. meeting?

74 Form N-PX filers reported votes at the meeting of 3 Dec 2025. On say-on-pay, 4 of 71 voted against management (5.6%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Galectin Therapeutics Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Galectin Therapeutics Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Galectin Therapeutics Inc. with a meeting date within three days of 3 Dec 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.